Bruker Corporation
BRKR
株式のランク
#2373
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
株価
$54.54
最終同期: 2026-10-16
時価総額
$8.31B
変化（1日）
-3.55%
変化（1年）
47.47%
国
US
取引 Bruker Corporation (BRKR)
カテゴリー
Healthcare
Bruker Corporation（BRKR）の営業利益率
October 2026 時点の営業利益率 TTM: 3.61%
Bruker Corporation の最新の財務報告と株価によると、現在の営業利益率（TTM）は 3.61% です。2023 年末時点では 14.74% でした。
Bruker Corporation の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 3.61% | -51.99% |
| 2024 | 7.52% | -48.98% |
| 2023 | 14.74% | -13.80% |
| 2022 | 17.10% | 0.06% |
| 2021 | 17.09% | 36.83% |
| 2020 | 12.49% | -13.98% |
| 2019 | 14.52% | 4.91% |
| 2018 | 13.84% | 13.82% |
| 2017 | 12.16% | 10.55% |
| 2016 | 11.00% | 22.63% |
| 2015 | 8.97% | 53.86% |
| 2014 | 5.83% | -27.67% |
| 2013 | 8.06% | -7.46% |
| 2012 | 8.71% | -7.54% |
| 2011 | 9.42% | -21.04% |
| 2010 | 11.93% | -2.77% |
| 2009 | 12.27% | 25.59% |
| 2008 | 9.77% | 7.01% |
| 2007 | 9.13% | 29.69% |
| 2006 | 7.04% | 97.20% |
| 2005 | 3.57% | -1,015.38% |
| 2004 | -0.39% | -89.49% |
| 2003 | -3.71% | -175.10% |
| 2002 | 4.94% | 39.94% |
| 2001 | 3.53% | 267.71% |
| 2000 | 0.96% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 17.03% | -95.28% |
US
|
|
| 17.86% | -95.05% |
IE
|
|
| 22.03% | -93.90% |
US
|
|
| 21.46% | -94.06% |
US
|
|
| 0.00% | - |
DE
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。